Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
		THE CURRENT TIME at LC Labs is:

E-4040 Everolimus, >99%

[SDZ-RAD] [Certican] [RAD001] [40-O-(2-hydroxyethyl)-rapamycin]

M.W. 958.24

C53H83NO14

[159351-69-6]

M.I. 14:  3907

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO and ethanol, up to about 25 mg/mL.  Disposal:  A

View the MSDS for this product

• Everolimus is an immunosuppressant analog of rapamycin (sirolimus) and inhibits growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells.  Chapman, T.M. and Perry, C.M.  "Everolimus."  Drugs 64:  861-874 (2004).

• Everolimus shows a potent inhibitory effect on posttransplant lymphoproliferative disorder (PTLD)-derived cells in vitro and in vivo, in a dose range that can prevent allograft rejection, and may demonstrate activity in both the prevention and treatment of PTLDs in transplant patients.  Majewski, M., et al.  "Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses."  Transplantation 75:  1710-1717 (2003).

• Oral everolimus inhibits in-stent neointimal growth in the rabbit iliac artery.  Everolimus was well tolerated at a dose of 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days and was related with significant neointimal healing.  Farb, A., et al.  "Oral Everolimus Inhibits In-Stent Neointimal Growth."  Circulation 106:  2379-2384 (2002).

• Everolimus is the active ingredient in the drug sold under the tradename Certican and in the drug-eluting stent sold under the tradename XienceV.  The drug is approved for prophylaxis of organ rejection in patients who have received a kidney or heart transplant, and the stent is approved for use in patients undergoing angioplasty.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Section 68B of the Patents Act of 1953 in New Zealand; (vi) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (vii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.